PAVmed to Hold a Business Update Conference Call on August 16, 2022
August 03 2022 - 8:25AM
Business Wire
Company conference call and webcast at 4:30 PM
EDT
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified
commercial-stage medical device company today announced that the
Company will host a business update conference call on Tuesday,
August 16, 2022, at 4:30 PM EDT. During the call, Lishan Aklog,
M.D., Chairman, and Chief Executive Officer, will provide a
business update including an overview of the Company’s operations
over the past quarter and its growth strategy. In addition, Dennis
McGrath, PAVmed’s Chief Financial Officer, will discuss the
Company’s second-quarter 2022 financial results.
To access the conference call, U.S.-based listeners should dial
877-407-3982 and international listeners should dial 201-493-6780.
All listeners should provide the operator with the conference call
name “PAVmed, Inc. Business Update Conference Call” to join.
Individuals interested in listening to the live conference call via
the webcast may do so by visiting the investor relations section of
the Company’s website at www.pavmed.com.
Following the conclusion of the conference call, a replay will
be available for one week and can be accessed by dialing
844-512-2921 from within the U.S. or 412-317-6671 from outside the
U.S. To access the replay, all listeners should provide the
following pin number: 13730495. The webcast will be available for
replay on the investor relations section of the Company’s website
at www.pavmed.com.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD) is a commercial-stage cancer prevention medical
diagnostics company which markets the EsoGuard® Esophageal DNA Test
and EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Lucid operates its
own CLIA-certified, CAP-approved molecular diagnostic laboratory,
LucidDx Labs and a network of Lucid Test Centers. Another major
subsidiary, Veris Health Inc., is a digital health company focused
on enhanced personalized cancer care through remote patient
monitoring using implantable biologic sensors with wireless
communication along with a custom suite of connected external
devices. The product pipeline also includes the CarpX® Minimally
Invasive Device for Carpal Tunnel Syndrome, EsoCure™ Esophageal
Ablation Device with Caldus™ Technology, which complements EsoGuard
and EsoCheck, NextFlo™ Intravenous Infusion Set, PortIO™
Implantable Intraosseous Vascular Access Device, and other earlier
stage technologies. For more information on PAVmed, please visit
PAVmed.com and follow PAVmed on Twitter, LinkedIn, and YouTube. For
more information on Lucid, please visit LucidDx.com and follow
Lucid on Twitter, and LinkedIn. For detailed information on
EsoGuard, please visit EsoGuard.com and follow EsoGuard on Twitter,
Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed’s common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance PAVmed’s products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed’s clinical and
preclinical studies; whether and when PAVmed’s products are cleared
by regulatory authorities; market acceptance of PAVmed’s products
once cleared and commercialized; PAVmed’s ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid has been monitoring the COVID-19 pandemic and
the pandemic’s impact on PAVmed’s businesses. Lucid expects the
significance of the COVID-19 pandemic, including the extent of its
effect on its financial and operational results, to be dictated by,
among other things, the success of efforts to contain the pandemic
and the impact of such efforts on PAVmed’s businesses. These
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. In addition, new risks and
uncertainties may arise from time to time and are difficult to
predict. For a further list and description of these and other
important risks and uncertainties that may affect PAVmed’s future
operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by
Lucid, as applicable, after its Registration Statement No.
333-259721 filed with the Securities and Exchange Commission.
PAVmed disclaims any intention or obligation to publicly update or
revise any forward-looking statement to reflect any change in its
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220801005160/en/
Investors Adrian K. Miller PAVmed
Inc. AKM@PAVmed.com Media Shani Lewis
LaVoieHealthScience (609) 516-5761
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Apr 2023 to Apr 2024